-
Je něco špatně v tomto záznamu ?
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
M. Nissen, B. Delcoigne, D. Di Giuseppe, L. Jacobsson, ML. Hetland, A. Ciurea, L. Nekvindova, F. Iannone, N. Akkoc, T. Sokka-Isler, KM. Fagerli, MJ. Santos, C. Codreanu, M. Pombo-Suarez, Z. Rotar, B. Gudbjornsson, I. van der Horst-Bruinsma, AG....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
Medline Complete (EBSCOhost)
od 1999-01-01 do Před 1 rokem
- MeSH
- antirevmatika * terapeutické užití MeSH
- axiální spondyloartritida * MeSH
- inhibitory TNF terapeutické užití MeSH
- lidé MeSH
- spondylartritida * farmakoterapie MeSH
- TNF-alfa MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.
Center of Rheumatic Diseases University of Medicine and Pharmacy Bucharest Romania
Centre for Rheumatology Research University Hospital
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet
Clinical Epidemiology Division Department of Medicine Solna Karolinska Institutet Stockholm
Department for Rheumatology and Immunology Inselspital University Hospital Bern Bern Switzerland
Department for Rheumatology University Hospital Reykjavik Iceland
Department of Clinical Medicine Aarhus University Aarhus Denmark
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Rheumatology Aarhus University Hospital
Department of Rheumatology Amsterdam UMC location VUmc Amsterdam Netherlands
Department of Rheumatology Hospital Garcia de Orta Almada
Department of Rheumatology University Hospital Zurich University of Zurich Zurich Switzerland
Department of Rheumatology University Medical Centre Ljubljana
Department of Rheumatology University of Lisbon Lisbon Portugal
Division of Rheumatology and Research Diakonhjemmet Hospital Oslo
Division of Rheumatology and Research Diakonhjemmet Hospital Oslo Norway
Division of Rheumatology Department of Medicine Celal Bayar University Manisa Turkey
Division of Rheumatology Geneva University Hospital Geneva Switzerland
Faculty of Medicine Charles University Prague
Faculty of Medicine University of Iceland Reykjavik Iceland
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Health Technology Assessment Agency of Carlos 3 Institute of Health Madrid Spain
Institute of Biostatistics and Analyses Ltd Brno Czech Republic
Rheumatology Inflammation Center Helsinki University Hospital Helsinki Finland
Rheumatology Service Hospital Clinico Universitario Santiago de Compostela Spain
Rheumatology Theme Inflammation and Ageing Karolinska University Hospital Stockholm Sweden
Rheumatology Unit DETO University of Bari Bari Italy
Sfanta Maria Hospital University of Medicine and Pharmacy Bucharest Romania
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032574
- 003
- CZ-PrNML
- 005
- 20230131150903.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/rheumatology/keac174 $2 doi
- 035 __
- $a (PubMed)35323903
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Nissen, Michael $u Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland $1 https://orcid.org/0000000263261764
- 245 14
- $a The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis / $c M. Nissen, B. Delcoigne, D. Di Giuseppe, L. Jacobsson, ML. Hetland, A. Ciurea, L. Nekvindova, F. Iannone, N. Akkoc, T. Sokka-Isler, KM. Fagerli, MJ. Santos, C. Codreanu, M. Pombo-Suarez, Z. Rotar, B. Gudbjornsson, I. van der Horst-Bruinsma, AG. Loft, B. Möller, H. Mann, F. Conti, G. Yildirim Cetin, H. Relas, B. Michelsen, P. Avila Ribeiro, R. Ionescu, C. Sanchez-Piedra, M. Tomsic, ÁJ. Geirsson, J. Askling, B. Glintborg, U. Lindström
- 520 9_
- $a OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a antirevmatika $x terapeutické užití $7 D018501
- 650 _2
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 650 12
- $a spondylartritida $x farmakoterapie $7 D025241
- 650 12
- $a axiální spondyloartritida $7 D000089183
- 650 _2
- $a TNF-alfa $7 D014409
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Delcoigne, Bénédicte $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm $1 https://orcid.org/0000000227165679
- 700 1_
- $a Di Giuseppe, Daniela $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm $1 https://orcid.org/0000000338178288
- 700 1_
- $a Jacobsson, Lennart $u Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/000000034402148X
- 700 1_
- $a Hetland, Merete Lund $u Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Glostrup $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
- 700 1_
- $a Ciurea, Adrian $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland $1 https://orcid.org/0000000278707132
- 700 1_
- $a Nekvindova, Lucie $u Faculty of Medicine, Charles University, Prague $u Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic
- 700 1_
- $a Iannone, Florenzo $u Rheumatology Unit, DETO, University of Bari, Bari, Italy $1 https://orcid.org/0000000304745344
- 700 1_
- $a Akkoc, Nurullah $u Division of Rheumatology, Department of Medicine, Celal Bayar University, Manisa, Turkey $1 https://orcid.org/000000023718171X
- 700 1_
- $a Sokka-Isler, Tuulikki $u University of Eastern Finland, Faculty of Health Sciences and Jyvaskyla Central Hospital, Jyvaskyla, Finland
- 700 1_
- $a Fagerli, Karen Minde $u Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway
- 700 1_
- $a Santos, Maria Jose $u Department of Rheumatology, Hospital Garcia de Orta, Almada $u Department of Rheumatology, University of Lisbon, Lisbon, Portugal $1 https://orcid.org/0000000279461365
- 700 1_
- $a Codreanu, Catalin $u Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Pombo-Suarez, Manuel $u Rheumatology Service, Hospital Clinico Universitario, Santiago de Compostela, Spain
- 700 1_
- $a Rotar, Ziga $u Department of Rheumatology, University Medical Centre Ljubljana $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Gudbjornsson, Bjorn $u Centre for Rheumatology Research (ICEBIO), University Hospital $u Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 700 1_
- $a van der Horst-Bruinsma, Irene $u Department of Rheumatology, Amsterdam UMC, location VUmc, Amsterdam, Netherlands
- 700 1_
- $a Loft, Anne Gitte $u Department of Rheumatology, Aarhus University Hospital $u Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Möller, Burkhard $u Department for Rheumatology and Immunology, Inselspital-University Hospital Bern, Bern, Switzerland $1 https://orcid.org/0000000187696167
- 700 1_
- $a Mann, Herman $u Institute of Rheumatology and Department of Rheumatology, Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Conti, Fabrizio $u Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Yildirim Cetin, Gozde $u Division of Rheumatology, Department of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
- 700 1_
- $a Relas, Heikki $u Rheumatology, Inflammation Center, Helsinki University Hospital, Helsinki, Finland
- 700 1_
- $a Michelsen, Brigitte $u Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo $u Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway
- 700 1_
- $a Avila Ribeiro, Pedro $u Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- 700 1_
- $a Ionescu, Ruxandra $u Sfanta Maria Hospital, University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Sanchez-Piedra, Carlos $u Health Technology Assessment Agency of Carlos III Institute of Health (AETS), Madrid, Spain
- 700 1_
- $a Tomsic, Matija $u Department of Rheumatology, University Medical Centre Ljubljana $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Geirsson, Árni Jón $u Department for Rheumatology, University Hospital, Reykjavik, Iceland
- 700 1_
- $a Askling, Johan $u Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet $u Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Glintborg, Bente $u DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital, Rigshospitalet, Glostrup $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000289318482
- 700 1_
- $a Lindström, Ulf $u Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/0000000222509348
- 773 0_
- $w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 61, č. 12 (2022), s. 4741-4751
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35323903 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150859 $b ABA008
- 999 __
- $a ok $b bmc $g 1891381 $s 1183909
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 61 $c 12 $d 4741-4751 $e 2022Nov28 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
- LZP __
- $a Pubmed-20230120
